Skip to content

Study · Randomized controlled trial · 2018

3 results

Serum Sclerostin Levels in Adults With Osteogenesis Imperfecta: Comparison With Normal Individuals and Response to Teriparatide Therapy.

Nicol L, Wang Y, Smith R, Sloan J, Nagamani SC, Shapiro J, Lee B, Orwoll E

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research7 Dec 2017Cited by 13 (Europe PMC)

PMID29044725 (opens in a new tab)DOI10.1002/jbmr.3312 (opens in a new tab)PepBankPUB-29044725
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialMechanism

    In adults with type I osteogenesis imperfecta, teriparatide increased serum sclerostin compared with placebo, significantly at 6, 12, and 24 months.

    In plain wordsIn adults with type I osteogenesis imperfecta, teriparatide increased blood sclerostin compared with placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseSerum sclerostin in type I OI
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    SOST levels increased in the group of patients with type I OI during therapy with teriparatide (compared with placebo, p = 0.01).
    2 context sentences
    Summary · context
    The increase was significant at 6, 12, and 24 months of therapy (p ≤ 0.02) and was apparent as early as 3 months (p = 0.06).
    Summary · context
    We measured serum SOST levels in adults with OI who were enrolled in a randomized, placebo-controlled clinical trial that evaluated the effects of osteoanabolic therapy with teriparatide.
  2. 02HumanRandomized controlled trialMechanism

    In adults with type I osteogenesis imperfecta, the early sclerostin increase during teriparatide therapy did not reach significance at 3 months.

    In plain wordsIn adults with type I osteogenesis imperfecta, the early sclerostin increase with teriparatide was not significant compared with placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeEarly serum sclerostin response
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    The increase was significant at 6, 12, and 24 months of therapy (p ≤ 0.02) and was apparent as early as 3 months (p = 0.06).
    2 context sentences
    Summary · context
    SOST levels increased in the group of patients with type I OI during therapy with teriparatide (compared with placebo, p = 0.01).
    Summary · context
    We measured serum SOST levels in adults with OI who were enrolled in a randomized, placebo-controlled clinical trial that evaluated the effects of osteoanabolic therapy with teriparatide.

Studies that did not test the peptide alone1

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 03HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther

    In adults with osteogenesis imperfecta receiving teriparatide, greater sclerostin increases were inversely correlated with vertebral volumetric BMD increases.

    In plain wordsIn adults receiving teriparatide for osteogenesis imperfecta, greater sclerostin increases were linked to smaller vertebral bone density increases.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseSclerostin response association with vertebral vBMD
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    The magnitude of increases in SOST levels during therapy was inversely correlated with increases in vertebral volumetric bone mineral density (vBMD).
    1 context sentence
    Summary · context
    We measured serum SOST levels in adults with OI who were enrolled in a randomized, placebo-controlled clinical trial that evaluated the effects of osteoanabolic therapy with teriparatide.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.